Overexpression of miR-200b inhibits the cell proliferation and promotes apoptosis of human hypertrophic scar fibroblasts in vitro

Journal of Dermatology

Volumn 41, Issue 10, 2014, Pages 903-911

  Li, Ping ^a   He, Quan Yong ^a   Luo, Cheng Qun ^a  

^a THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Collagen; Hypertrophic scarring; In vitro; miRNA 200b; TGF 1; SMA

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; FIBRONECTIN; MICRORNA 200B; TRANSFORMING GROWTH FACTOR BETA1; ACTA2 PROTEIN, HUMAN; ACTIN; CASPASE 3; CASPASE 8; COLLAGEN TYPE 3; CYCLINE; MICRORNA; MIRN200 MICRORNA, HUMAN; TGFB1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; FIBROBLAST; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYPERTROPHIC SCAR; HYPERTROPHY; IN VITRO STUDY; PROTEIN EXPRESSION; PROTEIN TARGETING; SCAR FORMATION; SKIN; ADOLESCENT; ADULT; BIOSYNTHESIS; CHILD; CICATRIX, HYPERTROPHIC; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; MALE; METABOLISM; PRESCHOOL CHILD; YOUNG ADULT;

ACTINS; ADOLESCENT; ADULT; APOPTOSIS; CASPASE 3; CASPASE 8; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; CICATRIX, HYPERTROPHIC; COLLAGEN TYPE I; COLLAGEN TYPE III; FEMALE; FIBROBLASTS; FIBRONECTINS; GENE EXPRESSION PROFILING; HUMANS; MALE; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; TRANSFORMING GROWTH FACTOR BETA1; YOUNG ADULT;

EID: 84908547664     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.12600     Document Type: Article

References (30)

1. Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med 2011; 17: 113-125.
2. Bayat A, McGrouther DA. Clinical management of skin scarring. Skinmed 2005; 4: 165-173.
3. Ong CT, Khoo YT, Tan EK et al. Epithelial-mesenchymal interactions in keloid pathogenesis modulate vascular endothelial growth factor expression and secretion. J Pathol 2007; 211: 95-108.
4. Soifer HS, Rossi JJ, Saetrom P. MicroRNAs in disease and potential therapeutic applications. Mol Ther 2007; 15: 2070-2079.
5. Mori M, Triboulet R, Mohseni M et al. Hippo signaling regulates microprocessor and links cell-density-dependent miRNA biogenesis to cancer. Cell 2014; 156: 893-906.
6. Yi R, O'Carroll D, Pasolli HA et al. Morphogenesis in skin is governed by discrete sets of differentially expressed microRNAs. Nat Genet 2006; 38: 356-362.
7. Ruzzo A, Graziano F, Vincenzi B et al. High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. Oncologist 2012; 17: 823-829.
8. Cheng J, Yu H, Deng S, Shen G. MicroRNA profiling in mid- and late-gestational fetal skin: implication for scarless wound healing. Tohoku J Exp Med 2010; 221: 203-209.
9. Liang P, Lv C, Jiang B et al. MicroRNA profiling in denatured dermis of deep burn patients. Burns 2012; 38: 534-540.
10. Liu Y, Yang D, Xiao Z, Zhang M. miRNA expression profiles in keloid tissue and corresponding normal skin tissue. Aesthetic Plast Surg 2012; 36: 193-201.
11. Gammell P. MicroRNAs: recently discovered key regulators of proliferation and apoptosis in animal cells: identification of miRNAs regulating growth and survival. Cytotechnology 2007; 53: 55-63.
12. Iorio MV, Casalini P, Piovan C et al. microRNA-205 regulates HER3 in human breast cancer. Cancer Res 2009; 69: 2195-2200.
13. Yu J, Lu Y, Cui D et al. miR-200b suppresses cell proliferation, migration and enhances chemosensitivity in prostate cancer by regulating Bmi-1. Oncol Rep 2014; 31: 910-918.
14. Park JT, Kato M, Yuan H et al. FOG2 protein down-regulation by transforming growth factor-beta1-induced microRNA-200b/c leads to Akt kinase activation and glomerular mesangial hypertrophy related to diabetic nephropathy. J Biol Chem 2013; 288: 22469-22480.
15. Tong J, Fu Y, Xu X et al. TGF-beta1 Stimulates Human Tenon's Capsule Fibroblast Proliferation by miR-200b and its Targeting of p27/kip1 and RND3. Invest Ophthalmol Vis Sci 2014; 55: 2747-2756.
16. Cutroneo KR. TGF-beta-induced fibrosis and SMAD signaling: oligo decoys as natural therapeutics for inhibition of tissue fibrosis and scarring. Wound Repair Regen 2007; 15(Suppl 1): S54-S60.
17. Chin GS, Liu W, Peled Z et al. Differential expression of transforming growth factor-beta receptors I and II and activation of Smad 3 in keloid fibroblasts. Plast Reconstr Surg 2001; 108: 423-429.
18. Profyris C, Tziotzios C, Do Vale I. Cutaneous scarring: pathophysiology, molecular mechanisms, and scar reduction therapeutics Part I. The molecular basis of scar formation. J Am Acad Dermatol 2012; 66 (1-10): 11-12.
19. Lu L, Saulis AS, Liu WR et al. The temporal effects of anti-TGF-beta1, 2, and 3 monoclonal antibody on wound healing and hypertrophic scar formation. J Am Coll Surg 2005; 201: 391-397.
20. Cordeiro MF, Mead A, Ali RR et al. Novel antisense oligonucleotides targeting TGF-beta inhibit in vivo scarring and improve surgical outcome. Gene Ther 2003; 10: 59-71.
21. Wang YW, Liou NH, Cherng JH et al. siRNA-Targeting Transforming Growth Factor-beta Type I Receptor Reduces Wound Scarring and Extracellular Matrix Deposition of Scar Tissue. J Invest Dermatol 2014; 134: 2016-2025.
22. Nicolae CM, Aho ER, Vlahos AH et al. The ADP-ribosyltransferase PARP10/ARTD10 interacts with Proliferating Cell Nuclear Antigen (PCNA) and is required for DNA damage tolerance. J Biol Chem 2014; 289: 13627-13637.
23. Akasaka Y, Ishikawa Y, Ono I et al. Enhanced expression of caspase-3 in hypertrophic scars and keloid: induction of caspase-3 and apoptosis in keloid fibroblasts in vitro. Lab Invest 2000; 80: 345-357.
24. Syed F, Ahmadi E, Iqbal SA et al. Fibroblasts from the growing margin of keloid scars produce higher levels of collagen I and III compared with intralesional and extralesional sites: clinical implications for lesional site-directed therapy. Br J Dermatol 2011; 164: 83-96.
25. Huang D, Shen KH, Wang HG. Pressure therapy upregulates matrix metalloproteinase expression and downregulates collagen expression in hypertrophic scar tissue. Chin Med J (Engl) 2013; 126: 3321-3324.
26. Kashiyama K, Mitsutake N, Matsuse M et al. miR-196a downregulation increases the expression of type I and III collagens in keloid fibroblasts. J Invest Dermatol 2012; 132: 1597-1604.
27. Zgheib C, Xu J, Liechty KW. Targeting Inflammatory Cytokines and Extracellular Matrix Composition to Promote Wound Regeneration. Adv Wound Care (New Rochelle) 2014; 3: 344-355.
28. Zhang Z, Garron TM, Li XJ et al. Recombinant human decorin inhibits TGF-beta1-induced contraction of collagen lattice by hypertrophic scar fibroblasts. Burns 2009; 35: 527-537.
29. Ashcroft KJ, Syed F, Bayat A. Site-specific keloid fibroblasts alter the behaviour of normal skin and normal scar fibroblasts through paracrine signalling. PLoS ONE 2013; 8: e75600.
30. Ray S, Ju X, Sun H et al. The IL-6 trans-signaling-STAT3 pathway mediates ECM and cellular proliferation in fibroblasts from hypertrophic scar. J Invest Dermatol 2013; 133: 1212-1220.